获取途径

作者

Yuan Tian Zixuan Feng Feng Feng Meng Fan Yu Hu Zhuoqi Li Yuanyuan Wang Kai Zhang & …Qi Dang

作者单位

⁵Gastrointestinal Surgery Department, Zhucheng People’s Hospital, Zhucheng, Shandong, 262200, P.R. China ⁷General Surgery Department, Wenshang County People’s Hospital, Wenshang, Shandong, 272500, P.R. China ⁴Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 252000, P.R. China ⁶Department of Oncology, The Second Affiliated Hospital of Shandong, University of Traditional Chinese Medicine, Jinan, Shandong, 250299, P.R. China ¹Phase I Clinical Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, No.440, Jiyan Road, Huaiyin District, Jinan, Shandong, 250117, P.R. China ²Radiotherapy Department, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, 250014, China ³Queen Mary School, Nanchang University, Nanchang, Jiangxi Province, 330006, P.R. China

刊名

Cancer Cell International

年份

2025

卷号

Vol.25 No.1

关键词

PD-1 PD-L1 Headache Risk Meta-analysis

摘要

Purpose This meta-analysis aimed to clarify the risk of headaches caused by programmed cell death 1 and programmed cell death ligand 1 inhibitors. Method Relevant clinical trials were screened using PubMed. The risk of headache associated with PD-1 or PD-L1 inhibitors was calculated using the mirror principle and PRISMA guidelines. Results A total of 33 clinical trials were screened for this comprehensive meta-analysis, yielding nine mirror-pairing groups. The risk of headache with PD-1 o...更多

Purpose This meta-analysis aimed to clarify the risk of headaches caused by programmed cell death 1 and programmed cell death ligand 1 inhibitors. Method Relevant clinical trials were screened using PubMed. The risk of headache associated with PD-1 or PD-L1 inhibitors was calculated using the mirror principle and PRISMA guidelines. Results A total of 33 clinical trials were screened for this comprehensive meta-analysis, yielding nine mirror-pairing groups. The risk of headache with PD-1 or PD-L1 inhibitors was significantly higher than that with placebo and similar to that with chemotherapy drugs . When PD-1 or PD-L1 inhibitors are combined with other immune-related drugs, the risk of headaches increases to varying degrees. However, when combined with chemotherapy, this risk did not increase significantly . Compared with PD-1, PD-L1 inhibitors were associated with a higher headache risk . Conclusion PD-L1 has a stronger effect on increasing headache risk than PD-1. Similar to the comparison of PD-1 or PD-L1 versus chemotherapy, PD-1 or PD-L1 plus chemotherapy did not significantly increase headache risk.收起

文献类型

期刊